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Key Points
•We report rare mono-
allelic variants of THPO
that alter intracellular
trafficking and diminish
thrombopoietin
secretion.
• Affected cases have
autosomal-dominant
thrombocytopenia but
no other hematological
features.
Introduction
Thrombopoietin (TPO) is a lineage-specific cytokine that is synthesized predominantly in hepatocytes
and is an essential regulator of self-renewal of hematopoietic stem cells and their differentiation into
platelet-forming megakaryocytes.1,2 The major TPO isoform is a 353-aa peptide containing a highly
glycosylated C-terminal domain and an amino-terminal receptor binding domain (RBD) that mediates
interaction with the TPO receptor (c-mpl) on hematopoietic cells.3-5 TPO is encoded by the THPO gene,
which maps to 3q27.1 and contains up to 6 coding exons.6
Increased TPO production caused by gain-of-function THPO variants results in the myeloproliferative
disorder thrombocythemia-1 (Online Mendelian Inheritance in Man #187950), in which the
circulating platelet count is elevated, sometimes causing bleeding or thrombosis.7-9 In contrast,
biallelic loss-of-function THPO variants result in a severe reduction in the platelet count and
multilineage bone marrow failure.10-12 Here, we present genetic and functional evidence that monoallelic
loss-of-function THPO variants also result in reduced platelet count but do not affect other circulating
blood cells.
Methods
Study subjects were enrolled into the National Institute for Health Research BioResource for Rare
Diseases between December 2012 and March 2017 or were referred for analysis with the
ThromboGenomics high-throughput diagnostic platform.13 All subjects provided informed written
consent in accordance with East of England–Cambridge South research ethics committee approvals
(13/EE/0325 and 10/H0304/66).14 Clinical and laboratory data were coded using Human Phenotype
Ontology terms.15 DNA preparation, sequencing, and variant calling were performed as described
previously.13,14
Using the BeviMed method for genetic association,16 we compared the genotypes at rare
nonsynonymous variants of 105 unrelated thrombocytopenia cases in the National Institute for Health
Research BioResource for Rare Diseases with those of the other 10152 unrelated participants who did
not have unexplained thrombocytopenia (supplemental Information). Thrombocytopenia cases were
defined as patients with a platelet count (PLT) ,130 3 109/L or with the Human Phenotype Ontology
term “thrombocytopenia” (HP:0001873). Study participants were recalled, and genotype calls were
confirmed by polymerase chain reaction DNA amplification and Sanger sequencing (supplemental
Information). Blood cell parameters were measured using a Sysmex XN-Series analyzer. Serum TPO
levels were measured using an enzyme-linked immunosorbent assay (ELISA; R&D Systems).
To further assess the pathogenicity of the THPO variants, pcDNA3.11 expression vectors containing
N-terminal FLAG-tagged wild-type (WT) THPO or the variant THPO complementary DNAs (cDNAs;
Submitted 2 December 2019; accepted 23 December 2019; published online 9
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GenScript) were transfected into cultured HEK293T cells. Cell
supernatants and lysates were collected 24 hours after trans-
fection, and the FLAG-tagged proteins were quantified by ELISA
(Cayman Chemical). Transfected cells stained with an antibody
against the FLAG epitope were examined by confocal immunoflu-
orescence microscopy (supplemental Information).
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Figure 1. Rare monoallelic variants in THPO are associated with thrombocytopenia. (A) Associations between rare filtered variants across all genes and case/control
groups defined by the presence of thrombocytopenia were inferred using the BeviMed method. Genes with a posterior probability of association .0.4 are shown for dominant
and recessive inheritance models. Genes previously associated with thrombocytopenia are shown as blue symbols, whereas those with no confirmed association are shown as
gray symbols. (B) Pedigree structures of the 3 index cases (A, II.2; B, I.2; and C, II.1) and pedigree members, indicating the presence (black symbols) or absence (white
symbols) of thrombocytopenia and cases with unknown PLT (gray symbols). Genotypes confirmed by Sanger sequencing are annotated against canonical transcript
ENST00000204615.7 (GRCh37.p13). wt/wt indicates homozygous for the reference allele. wt/* indicates the monoallelic variant. (C) Schematic diagram of the wt and
predicted variant TPO proteins with amino acid numbering indicating the signal peptide (1-21), RBD (22-152), and C-terminal domain (153-353). Black circles indicate the
position of consensus N-linked glycan sites. The insertion variants p.E204fs*123 and p.L269Pfs*58 (*) predict altered amino acid sequence (shaded region) downstream of the
variant site and chain truncation, both after codon 327. The predicted p.R99W variant (*) is in the RBD. (D) Phylogenetic conservation of R99 across representative mamma-
lian species shown in a sequence line up prepared using Clustal Omega. (E) Ribbon diagram of the TPO RBD derived from PDB:1V7M with direct contact regions between
TPO and the TPO receptor indicated in red and the 4 helical regions indicated as A, B, C, and D. In the expanded view (left panel) and detailed vertical view (right panel), the
wt R99 (green side chain) occurs in the cross-over region between helices A and B in the wt TPO peptide. Substitution of R99 with a W (blue) residue introduces a amphi-
pathic residue with a bulky aromatic side chain into the space between helices B and C.
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Results and discussion
To identify new genes or modes of inheritance for heritable
thrombocytopenia, we evaluated whole-genome sequence data
for 33 814 genes using the BeviMed method for genetic
association. Sixteen genes had a posterior probability of association
with thrombocytopenia .0.4, of which 13 have previously been
shown to harbor variants causal of thrombocytopenia in multiple
pedigrees (Figure 1A). Of the remainder, only THPO harbored rare
variants with a high probability of pathogenicity that segregated with
thrombocytopenia in family members.
Of the 4 heterozygous variants contributing to the high posterior
probability of association between THPO and thrombocytopenia, 2
occurred in pedigrees that were available for further phenotype
testing (Figure 1B; pedigrees A and C). A third thrombocytopenic
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Figure 2. Phenotypic characteristics of monoallelic THPO variants and expression in HEK293T cells. (A) Sex-stratified graphs of PLT and mean platelet volume
obtained using a Sysmex XN-Series hematology analyzer from 48 345 blood donors from the INTERVAL study.17 The arrows indicate the platelet parameters of the cases
harboring THPO variants. (B) Representative May-Gru¨nwald-Giemsa–stained peripheral blood films from THPO variant cases confirming thrombocytopenia and indicating that
some platelets (arrows) were enlarged. Scale bars, 5 mM. (C) Serum TPO concentration plotted against platelet counts in healthy controls or hemato-oncology patients with
thrombocytopenia caused by bone marrow suppression after chemotherapy. Corresponding data from 4 cases with THPO variants (A I.1 and II.2, B I.2, C II.1) are also shown.
The solid and dotted lines represent the line of best-fit and 95% confidence intervals, respectively, from a nonlinear regression of control data. (D) Effects of THPO variants in
HEK293T cells: Flag-tagged WT, E204Gfs*123, L269P*58, or R99W substituted TPO was expressed in HEK293T cells by transient transfection. Secretion of FLAG-tagged
TPO in cell supernatant (D) and lysate (E) was measured using an ELISA and normalized against total protein in the cell lysate. Results are mean 6 standard error from $5
independent experiments. The P values were calculated using 1-way analysis of variance. (F) Representative images from HEK293T cells transfected with WT and variant
THPO cDNAs and stained with an antibody against the FLAG epitope (red). Nuclei were stained with 49,6-diamidino-2-phenylindole (blue). Images were captured using a Leica
SP5 II confocal microscope with a 633/1.4 NA lens and analyzed with ImageJ/Fiji. All images are shown with the same intensity range. (G) Quantification of FLAG-tagged
protein by mean fluorescence intensity in representative cells (n 5 5).
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case carrying a rare heterozygous THPO variant was identified in the
ThromboGenomics collection of cases with undiagnosed bleeding
and platelet disorders (Figure 1B; pedigree B). The variants included
2 single-nucleotide insertions (pedigree A, c.610dup; p.E204Gfs*123
and pedigree B, c.805dup; p.L269Pfs*58), both predicting a TPO
peptide with an abnormal C terminus with a stop gain after codon 327
causing chain truncation (Figure 1C). The other variant was amissense
single-nucleotide variant (pedigree C, c.295C.T; p.R99W) identified
in a single case but absent in other available family members
(Figure 1B). The substituted TPO R99 residue is highly conserved
across eukaryotes (Figure 1D) and is located between a-helices A and
B in the TPO RBD, distinct from residues that interface with the
TPO receptor.5 Substitution of the charged polar R99 with W has
a high CADD score of 33.017 and introduces a bulky amphipathic
residue between TPO helical domains B and C (Figure 1E).
The 3 index cases and 3 accessible family members with THPO
variants had reduced PLT (median, 120.53 109/L; range, 102-143)
and increased mean platelet volume (median, 12.4 fL; range, 12.1-
14.2) compared with ;50000 blood donors from the INTERVAL
study (Figure 2A).18 Blood films confirmed thrombocytopenia and
showed platelet anisocytosis with some large platelets (Figure 2B).
There were no other quantitative blood cell abnormalities (supple-
mental Information). Mild mucocutaneous bleeding was reported in 4
cases, but there were no other consistent phenotypic features. The
median serum TPO concentration in the subjects was 42 pg/mL
(range, 17-57; n 5 4), which was lower than expected for PLT
compared with 35 controls who were healthy or who had low PLT
following chemotherapy for hematological malignancy (Figure 2C).
To further assess the pathogenicity of the THPO variants, FLAG-
tagged WT or variant THPO cDNAs were transfected into
HEK293T cells. FLAG-tagged TPO (FLAG-TPO) concentrations
measured by immunoassay were lower in the culture supernatants
of the variant-transfected cells compared with WT-transfected
controls (Figure 2D). These findings strongly support pathogenicity
of the observed variants and indicate that thrombocytopenia in the
cases results from diminished secretion of TPO.
In cell lysates, the FLAG-TPO concentration in E204Gfs*123 cells was
markedly higher than in WT controls (Figure 2E). This was confirmed
by confocal immunofluorescence microscopy (Figure 2F-G) and
suggests that secretion failure occurs because of mistrafficking and
cytoplasmic accumulation of the substituted TPO. Lysates from the
L269Pfs*58 and R99W cells contained similar overall concen-
trations of FLAG-TPO asWT control cells (Figure 2E). However, these
substituted TPO peptides showed greater perinuclear localization and
less punctate cytoplasmic expression comparedwithWT (Figure 2F-G).
This appearance also suggests mistrafficking, although, with these
variants, the substituted TPO proteins appear to accumulate in the
Golgi and undergo intracellular degradation rather than accumulating
in the cytoplasm. Although these observations provide an attractive
mechanism for the reduction in TPO secretion, it is premature to
extrapolate these findings in heterologous cells to make inferences
about endogenous TPO production in the study cases.
It has been shown previously that mutagenesis of glycosylated
residues in the TPO C terminus or chain truncation disrupt TPO
secretion,3,19 suggesting that this domain has an essential function
in ensuring appropriate trafficking to the secretory compartment.
Our findings with the E204Gfs*123 and L269Pfs*58 variants are
consistent with this hypothesis, because these variants result in loss
of TPO C-terminal domain glycosylated residues (Figure 1C). The
monoallelic R99W variant is not predicted to truncate the TPO
C-terminal domain; instead, it is likely to alter TPO tertiary structure,
potentially disrupting trafficking. Pathogenicity of the R99W variant
is further supported by observations from other investigators that
biallelic R99W variants caused trilineage bone marrow failure in 2
pedigrees in which affected cases had undetectable serum TPO,11
suggesting defective TPO secretion. It is also noteworthy that
thrombocytopenia is sometimes part of the complex phenotype
associated with microdeletions of the 3q26.33-3q27.2 region that
includes THPO.20-22 A high-impact monoallelic THPO variant predict-
ing p.R31* has also been reported previously in 2 pedigreeswith isolated
thrombocytopenia, although it was not characterized functionally.23
Heritable thrombocytopenia is a heterogeneous group of disorders
associated with variants in a rapidly expanding number of genes,
including some associated with severe bleeding, leukemia suscep-
tibility, or nonhematological phenotypes.24,25 Our findings extend
the repertoire of this group of disorders and establish that THPO-
related thrombocytopenia is caused by monoallelic loss-of-function
variants in THPO that result in reduced TPO secretion. Our data
suggest that monoallelic THPO variants confer a mild clinical
phenotype with abnormalities confined to the platelet lineage.
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